Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2009

01-02-2009 | Endocrine Tumors

Principal Component Analysis, Hierarchical Clustering, and Decision Tree Assessment of Plasma mRNA and Hormone Levels as an Early Detection Strategy for Small Intestinal Neuroendocrine (Carcinoid) Tumors

Authors: Irvin M. Modlin, MD, PhD, DSc, FRCS (Eng & Ed), Björn I. Gustafsson, Ignat Drozdov, Boaz Nadler, Roswitha Pfragner, Mark Kidd

Published in: Annals of Surgical Oncology | Issue 2/2009

Login to get access

Abstract

Incidence of neuroendocrine tumors (NETs) is increasing (approximately 6%/year), but clinical presentation is nonspecific, resulting in delays in diagnosis (5–7 years; approximately 70% have metastases). This reflects absence of a sensitive plasma marker. The aim of this study is to investigate whether detection of circulating messenger RNA (mRNA) alone or in combination with circulating NET-related hormones and growth factors can detect gastrointestinal NET disease. The small intestinal (SI) NET cell line KRJ-I was used to define the sensitivity of real-time polymerase chain reaction (PCR) for mRNA detection in blood. NSE, Tph-1, and VMAT 2 transcripts were identified from one KRJ-I cell/ml blood. mRNA from the tissue and plasma of SI-NETs (n = 12) and gastric NETs (n = 7), and plasma from healthy controls (n = 9) was isolated and real-time PCR performed. Tph-1 was a specific marker of SI-NETs (58%, p < 0.03) whereas CgA transcripts did not differentiate tumors from controls. Patients with metastatic disease expressed more marker transcripts than localized tumors (75% versus 18%, p < 0.02). Plasma 5-hydroxytryptamine (5-HT), chromogranin A (CgA), ghrelin, and connective tissue growth factor (CTGF) fragments were measured, combined with mRNA levels, and a predictive mathematical model for NET diagnosis developed using decision trees. The sensitivity and specificity to diagnose SI-NETs and gastric NETs were 81.2% and 100%, and 71.4% and 55.6%, respectively. We conclude that mRNA from one NET cell/ml blood can be detected. Circulating plasma Tph-1 is a promising marker gene for SI-NET disease (specificity 100%) while an increased number of marker transcripts (>2) correlated with disease spread. Including NET-related circulating hormones and growth factors in the algorithm increased the sensitivity of detection of SI-NETs from 58 to 82%.
Literature
1.
Cleary S, Phillips JK, Huynh TT, et al. Chromogranin a expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Horm Metab Res. 2007;39:876–83.PubMedCrossRef
2.
Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol. 2008;20:1–12.PubMed
3.
Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Phys. 2003;68:1075–82.
4.
Visus C, Andres R, Mayordomo JI, et al. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma. Melanoma Res. 2007;17:83–9.PubMedCrossRef
5.
Cristofanilli M, Broglio KR, Guarneri V, et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007;7:471–9.PubMedCrossRef
6.
Pfitzenmaier J, Ellis WJ, Hawley S, et al. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urol Oncol. 2007;25:214–20.PubMed
7.
Zitt M, Zitt M, Muller HM, et al. Disseminated tumor cells in peripheral blood: a novel marker for therapy response in locally advanced rectal cancer patients undergoing preoperative chemoradiation. Dis Colon Rectum. 2006;49:1484–91.PubMedCrossRef
8.
Wu CH, Lin SR, Hsieh JS, et al. Molecular detection of disseminated tumor cells in the peripheral blood of patients with gastric cancer: evaluation of their prognostic significance. Dis Markers. 2006;22:103–9.PubMed
9.
Dawood S, Cristofanilli M. Integrating circulating tumor cell assays into the management of breast cancer. Curr Treat Options Oncol. 2007;8:89–95.PubMedCrossRef
10.
Moreno JG, O’Hara SM, Gross S, et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology. 2001;58:386–92.PubMedCrossRef
11.
Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–904.PubMedCrossRef
12.
Anker P, Mulcahy H, Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int J Cancer. 2003;103:149–52.PubMedCrossRef
13.
Lo KW, Lo YM, Leung SF, et al. Analysis of cell-free Epstein–Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem. 1999;45:1292–4.PubMed
14.
Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res. 1999;5:1961–5.PubMed
15.
Goebel G, Zitt M, Zitt M, Muller HM. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers. 2005;21:105–20.PubMed
16.
YK, Lo YM. Diagnostic developments involving cell-free (circulating) nucleic acids. Clin Chim Acta 2006;363:187–96.CrossRef
17.
El-Hefnawy T, Raja S, Kelly L, et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 2004;50:564–73.PubMedCrossRef
18.
de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:33–41.PubMedCrossRef
19.
Stridsberg M, Oberg K, Li Q, et al. Measurement of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995;144:49–59.PubMedCrossRef
20.
Kidd M, Modlin IM, Shapiro MD, et al. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J Gastroenterol. 2007;13:5208–16.PubMed
21.
Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer. 2005;103:1587–95.PubMedCrossRef
22.
Modlin IM, Kidd M, Pfragner R, et al. The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab. 2006;91:2340–8.PubMedCrossRef
23.
Kidd M, Modlin IM, Mane SM, et al. The role of genetic markers—NAP1L1, MAGE-D2, and MTA1—in defining small-intestinal carcinoid neoplasia. Ann Surg Oncol. 2006;13:253–62.PubMedCrossRef
24.
Kidd M, Eick GN, Modlin IM, et al. Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. J Mol Endocrinol. 2007;38:181–92.PubMedCrossRef
25.
Kidd M, Nadler B, Mane S, et al. GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for real-time PCR. Physiol Genomics. 2007;30:363–70.PubMedCrossRef
26.
Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003;177:337–41.PubMedCrossRef
27.
Patterson M, Murphy KG, le Roux CW, et al. Characterization of ghrelin-like immunoreactivity in human plasma. J Clin Endocrinol Metab. 2005;90:2205–11.PubMedCrossRef
28.
Jaffa AA, Usinger WR, McHenry MB, et al. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab. 2008.
29.
Partek. Partek® genomics suiteTM. St. Louis: Partek Inc.; 2008.
30.
Mohlig M, Floter A, Spranger J, et al. Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling. Diabetologia. 2006;49:2572–9.PubMedCrossRef
31.
Jolliffe IT. Principle component analysis. New York: Springer; 1986.
32.
Zhang H, Singer B. Recursive partitioning in the health sciences (statistics for biology and health). New York: Springer; 1999.
33.
Sciarra A, Monti S, Gentile V, et al. Chromogranin A expression in familial versus sporadic prostate cancer. Urology. 2005;66:1010–4.PubMedCrossRef
34.
Bondioni S, Mantovani G, Polentarutti N, et al. Evaluation of proopiomelanocortin mRNA in the peripheral blood from patients with Cushing’s syndrome of different origin. J Endocrinol Invest. 2007;30:828–32.PubMed
35.
Fukuda ME, Iwadate Y, Machida T, et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res. 2005;65:5190–4.PubMedCrossRef
36.
Cimitan M, Buonadonna A, Cannizzaro R, et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol. 2003;14:1135–41.PubMedCrossRef
37.
Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood. 1993;82:2605–10.PubMed
38.
Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:2023–9.PubMedCrossRef
39.
Pfragner R WG, Niederle B, Behmel A, Rinner I, Mandl A, Wawrina F, et al. Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I): characterization and effects of 5-azacytidine on proliferation. Int J Oncol. 1996;8:513–20.
40.
Syversen U, Ramstad H, Gamme K, et al. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol. 2004;39:969–73.PubMedCrossRef
41.
Ford JK, MacCallum RC, Tait M. The application of exploratory factor analysis in applied psychology: a critical review and analysis. Personnel Psychol. 1986;39:291–314.CrossRef
42.
Domingos P. Occam’s two razors: the sharp and the blunt. In: Agrawal R, Stolorz P (editors) Proceedings of the Fourth International Conference on Knowledge Discovery and Data Mining. New York: AAAI; 1998.
43.
Oates T, Jensen D. The Effects of training set size on decision tree complexity. In: Proceedings of the fourteenth international conference on machine learning. Nashville: Morgan Kaufmann; 1997.
44.
Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717–51.PubMedCrossRef
45.
Borch K, Ahren B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242:64–73.PubMedCrossRef
46.
Modlin I, Sachs G. Acid related diseases-biology and treatment. Philadelphia: Lippincott Williams and Wilkins; 2004.
47.
Xi L, Nicastri DG, El-Hefnawy T, et al. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem. 2007;53:1206–15.PubMedCrossRef
Metadata
Title
Principal Component Analysis, Hierarchical Clustering, and Decision Tree Assessment of Plasma mRNA and Hormone Levels as an Early Detection Strategy for Small Intestinal Neuroendocrine (Carcinoid) Tumors
Authors
Irvin M. Modlin, MD, PhD, DSc, FRCS (Eng & Ed)
Björn I. Gustafsson
Ignat Drozdov
Boaz Nadler
Roswitha Pfragner
Mark Kidd
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0251-1

Other articles of this Issue 2/2009

Annals of Surgical Oncology 2/2009 Go to the issue

Gastrointestinal Oncology

Polymorphisms of p16, p27, p73, and MDM2 Modulate Response and Survival of Pancreatic Cancer Patients Treated with Preoperative Chemoradiation

Endocrine Tumors

Effectiveness of Peripheral Thyrotropin Receptor mRNA in Follow-Up of Differentiated Thyroid Cancer

Laboratory and Translational Research

Identification of Calreticulin as a Prognosis Marker and Angiogenic Regulator in Human Gastric Cancer

Head and Neck Oncology

Analysis of Differential BRAFV600E Mutational Status in High Aggressive Papillary Thyroid Microcarcinoma

Hepatobiliary and Pancreatic Tumors

Induction of Tumor Growth After Preoperative Portal Vein Embolization: Is It a Real Problem?

Bone and Soft Tissue Sarcomas

Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)